Literature DB >> 7795214

AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.

G Nucifora1, J D Rowley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795214

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  52 in total

1.  Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Authors:  Ming Yan; Sebastien A Burel; Luke F Peterson; Eiki Kanbe; Hiromi Iwasaki; Anita Boyapati; Robert Hines; Koichi Akashi; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

Review 2.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.

Authors:  M D Aljurf; S Z Zaidi; H El Solh; F Hussain; A Ghavamzadeh; H K Mahmoud; T Shamsi; T Ben Othman; M M Sarhan; D Dennison; A Ibrahim; S Benchekroun; N Chaudhri; B Labar; M Horowitz; D Niederwieser; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

Review 5.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

6.  The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.

Authors:  S Scheidler; W J Fredericks; F J Rauscher; F G Barr; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.

Authors:  M S Petrovick; S W Hiebert; A D Friedman; C J Hetherington; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

8.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

9.  Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.

Authors:  Russell C DeKelver; Ming Yan; Eun-Young Ahn; Wei-Jong Shia; Nancy A Speck; Dong-Er Zhang
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

10.  Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability.

Authors:  Eun Ji Choi; Min Sung Kim; Sang Yong Song; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2016-09-13       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.